1. Scrip
  2. >>Advanced Therapies

Stoke Gets Runway, Biogen A Late-Stage Asset In Epilepsy Collaboration

 
• By Joseph Haas

Biogen will pay $165m up front for ex-North American rights to Stoke’s Phase III-ready Dravet syndrome candidate, an antisense drug offering disease-modifying potential.

Epilepsy
Stoke is partnering with Biogen on its antisense candidate for a rare type of epilepsy

In what observers are calling a sensible deal for both sides, Stoke Therapeutics and Biogen revealed on 18 February that they will collaborate on development and commercialization of Stoke’s antisense oligonucleotide (ASO) therapy for Dravet syndrome, zorevunersen (STK-001). The deal brings Stoke added financial runway and an experienced commercial partner that has succeeded with ASO therapies, while Biogen obtains a late-stage candidate that may offer blockbuster sales in an underserved rare disease.

Key Takeaways
  • Stoke is partnering its Phase III-ready Dravet syndrome candidate with Biogen in a deal that brings Stoke increased financial runway and an ideal commercial partner outside of North America.

Cambridge, MA-based Stoke reported encouraging Phase I/IIa data for zorevunersen last March indicating that its drug demonstrated an ability to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Advanced Therapies

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 
• By Alexandra Shimmings

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

Rocket Comes Back To Earth With Restructuring Plan

 
• By Alaric DeArment

The biotech will lay off nearly one-third of its workforce and focus on its cardiovascular gene therapy programs.

Dispatch Uses ‘Flare’ To Send CAR-Ts To Solid Tumors

 
• By Alaric DeArment

With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.

The Duchenne Gene Therapies Lining Up To Take Elevidys’ Place

 
• By Andrew McConaghie

Regenxbio and Solid Biosciences believe they have a next-generation approach to AAV-based gene therapies – but must distance themselves from Sarepta’s safety and efficacy problems.

More from Therapy Areas

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By Manas Mishra

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.